Company intelligence / Profile preview

Nastech Pharmaceutical Company Inc.

Bothell, Washington, United Statessec.gov ↗

Ownership: Private
Employees: ~80
Development stage: Phase 2

Overview

Nastech had multiple products in Phase 2 clinical testing, including PYY for obesity and insulin for type 2 diabetes. The company also had positive results from clinical trials for intranasal morphine gluconate for pain management and teriparatide nasal spray for osteoporosis.

Therapeutic areas: PulmonologyMen's HealthEndocrinologyImmunologyOncologyNeurologyInfectious Diseases
Modalities: Intranasal drug deliveryRNA interference (RNAi)
Industry: Biotech

Drug pipeline

5 assets

apomorphine

Phase 2

Indications: Sexual dysfunction

4 more assets in the full pipeline.

Request access →

Partnerships

PharmaciaProcter & Gamble Pharmaceuticals

Beyond the preview

Go deeper on Nastech Pharmaceutical Company Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nastech Pharmaceutical Company Inc..

Explore the full profile